About EpiPen®

EpiPen

EpiPen® (Adrenaline)

EpiPen® auto-injectors are automatic injection devices containing adrenaline for allergic emergencies.

EpiPen® and EpiPen® Jr are indicated in the emergency treatment of severe allergic reactions (anaphylaxis) to insect stings or bites, foods, drugs and other allergens as well as idiopathic or exercise induced anaphylaxis.1,2

The active ingredient and instructions for use are the same for EpiPen® and EpiPen® Jr so the information in these pages is applicable for EpiPen® or EpiPen®Jr and the term EpiPen® is used throughout to refer to both interchangeably.

Anyone who has been prescribed an adrenaline auto-injector because of the risk of anaphylaxis should carry two with them at all times for emergency, on-the-spot use.3

Up to 35% of patients may require more than one adrenaline dose, 5-15 minutes after the first injection, in the absence of clinical improvement or if deterioration occurs after the initial treatment..4 Additionally, around 20% of patients may go on to develop a biphasic anaphylactic reaction many hours later.5

References:

  1. EpiPen® (adrenaline) Auto-Injector 0.3mg Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/4289/smpc. Last accessed: November 2022
  2. EpiPen® Jr (adrenaline) Auto-Injector 0.15mg Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/4290/smpc. Last accessed: November 2022
  3. Drug Safety Update Volume 11 Issue 1, August 2017: A3. Available at: https://www.gov.uk/drug-safety-update/adrenaline-auto-injectors-updated-... Last accessed: November 2022     
  4. Korenblat, P., Lundie, M.J., Dankner, R.E. and Day, J.H., 1999, November. A retrospective study of epinephrine administration for anaphylaxis: how many doses are needed?. In Allergy and Asthma Proceedings (Vol. 20, No. 6, pp. 383-386). OceanSide Publications; 1999.
  5. Kemp, S.F., Lockey, R.F., Simons, F.E.R. and World Allergy Organization ad hoc Committee on Epinephrine in Anaphylaxis, 2008. Epinephrine: the drug of choice for anaphylaxis--a statement of the World Allergy Organization. World Allergy Organization Journal, 1(S2), p.S18.

Mode of Action & Efficacy

EpiPen Child

Adrenaline is the first-line treatment for severe allergic reactions to food, insect stings, medication, latex, exercise and other allergens.

Adrenaline acts fast and rapidly treats all of the most dangerous symptoms of anaphylaxis, including throat swelling, difficulty breathing and low blood pressure.1 It also helps alleviate itching, rash, swelling, gastrointestinal and genitourinary symptoms.2,3 It works most effectively if it is given within the first few minutes of a severe allergic reaction.1

Adrenaline MOA
ADRENALINE

Adrenaline MOA

EpiPen® is an adrenaline auto-injector (AAI) used for self administration of adrenaline for the emergency treatment of anaphylaxis.4,5

  • EpiPen® delivers the correct dose of adrenaline quickly4,5
  • EpiPen® has needle protection which deploys immediately after administration4,5
  • EpiPen® has familiar jab administration and quickest injection hold time during administration in an emergency4,5

EpiPen table 

References:

  1. Muraro, A., Roberts, G., Worm, M., Bilò, M.B., Brockow, K., Fernández Rivas, M., Santos, A.F., Zolkipli, Z.Q., Bellou, A., Beyer, K. and Bindslev‐Jensen, C., 2014. Anaphylaxis: guidelines from the E uropean A cademy of A llergy and C linical I mmunology. Allergy, 69(8), pp.1026-1045.
  2. Drug Safety Update-Adrenaline auto-injectors: updated advice after European review Available at: https://www.gov.uk/drug-safety-update/adrenaline-auto-injectors-updated-... Last accessed: November 2022.
  3. Kemp, S.F et al, 2008. Epinephrine: the drug of choice for anaphylaxis--a statement of the World Allergy Organization. World Allergy Organization Journal, 1(S2), p.S18.
  4. EpiPen® (adrenaline) Auto-Injector 0.3mg SPC, Available at: https://www.medicines.org.uk/emc/product/4289/smpc. Last accessed November 2022.
  5. EpiPen® Jr (adrenaline) Auto-Injector 0.15mg SPC. Available at: https://www.medicines.org.uk/emc/product/4290/smpc. Last accessed: November 2022.

Treatment, Dosing & Administration

EpiPen

 The preferred route of administration of adrenaline for initial treatment of anaphylaxis is intramuscular.1

Adrenaline has a vasodilator effect in skeletal muscle, skeletal muscle is well vascularised; after intramuscular injection into the vastus lateralis (mid-anterolateral thigh), absorption is rapid and adrenaline reaches the central circulation rapidly; rapid absorption is important in anaphylaxis, in which the median times to cardiorespiratory arrest are reported as 5 minutes Iatrogenic (injected medication), 15 minutes (stinging insect venom), 30 minutes (food).2

Adrenaline auto-injectors are prescribed for self-administration and should be administered as soon as anaphylaxis is identified. It is possible that a biphasic reaction may occur, which is one of the reasons why guidelines state that patients should be prescribed 2 adrenaline autoinjectors which they should carry at all times.3

EAACI anaphylaxis guidelines recommend the following doses of adrenaline for self-administration, to be given by intramuscular injection.3

  • For adult and child body weight 25kg and above - 0.3mg
  • For child body weight 7.5 kg- 25kg - 0.15mg

EpiPen and EpiPen Jr

Instructions for use4,5

  1. Grasp EpiPen® auto injector in dominant hand, with thumb closest to blue safety cap
  2. With the other hand pull off blue safety cap
  3. Hold the EpiPen® auto injector at a distance of approximately 10 cm away from the outer thigh. The orange tip should point towards the outer thigh
  4. Jab firmly into the outer thigh, so that the EpiPen® auto injector is at a right-angle (at a 90 degree angle) to the outer thigh
  5. Hold firmly in place for 3 seconds. The injection is now complete and the window of the auto injector is obscured. The EpiPen® auto injector should be removed (the orange needle cover will extend to cover needle) and safely discarded
  6. Call 999

When to use

Anaphylaxis is unpredictable, and while a person may have a mild reaction one time, a serious or even life-threatening reaction can occur the next time. In addition, allergic reaction can begin with mild symptoms and then progress to a full anaphylactic episode.6

A person who is having an allergic reaction should use their EpiPen® immediately if they experience ANY of the following serious symptoms of anaphylaxis following contact with their allergen:4,5

  • Feeling light-headed or faint
  • Breathing difficulties, such as fast, shallow breathing
  • Wheezing
  • A fast heartbeat
  • Clammy skin
  • Confusion and anxiety
  • Collapsing or losing consciousness

Other allergy symptoms may include an itchy, raised rash (hives), feeling or being sick, swelling (angioedema) or stomach pain.4,5

References:

  1. Muraro, A et al., 2014. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy, 69(8), pp.1026-1045.
  2. Simons, F.E.R., 2011. World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organization Journal, 4(2), pp.13-37.
  3. Drug Safety Update Volume 11 Issue 1, August 2017: A3. Available at: https://www.gov.uk/drug-safety-update/adrenaline-auto-injectors-updated-... Last accessed: November 2022.
  4. EpiPen® (adrenaline) Auto-Injector 0.3mg Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/4289/smpc. Last accessed: November 2022.
  5. EpiPen® Jr (adrenaline) Auto-Injector 0.15mg Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/4290/smpc. Last accessed: November 2022.
  6. NHS anaphylaxis. Available at: https://www.nhs.uk/conditions/anaphylaxis/. Last Accessed: November 2022.

Prescribing Information

PRESCRIBING INFORMATION

EpiPen®(Adrenaline) Auto-injector 0.3 mg &
EpiPen® Jr. (Adrenaline) Auto-injector 0.15 mg


Please refer to Summary of Product Characteristics (SmPC) before prescribing.

Indications: EpiPen® auto injectors are automatic injection devices containing adrenaline for allergic emergencies. The auto injectors should be used only by a person with a history or an acknowledged risk of an anaphylactic reaction. The autoinjectors are indicated in the emergency treatment of allergic anaphylactic reactions. Anaphylaxis may be caused by insect stings or bites, foods, drugs and other allergens as well as idiopathic or exercise-induced anaphylaxis.

Presentation: EpiPen® delivers a single dose of 0.3mg of adrenaline BP 1:1000 (0.3ml) in a sterile solution. EpiPen® Jr. delivers a single dose of 0.15mg adrenaline BP 1:2000 (0.3ml) in a sterile solution. 1.7ml of adrenaline remains in the auto-injector after activation.

Dosage and administration: ADULTS: Administration of 0.3mg adrenaline (EpiPen®) intramuscularly. CHILDREN: The appropriate dosage may be 0.15mg (EpiPen® Jr.) for children 7.5-25kg body weight and 0.3mg (EpiPen®) adrenaline for children >25kg body weight, or at the discretion of the physician. EpiPen® should only be injected into the anterolateral aspect of the thigh through clothing if necessary. An initial dose should be administered as soon as symptoms of anaphylaxis are recognised. A second injection with an additional EpiPen® may be administered 5-15 minutes after the first injection, if indicated. It is recommended that patients are prescribed two EpiPen® auto-injectors which they should carry at all times. As EpiPen® is designed for emergency treatment, the patient should always seek medical help immediately.

Contra-indications: There are no absolute contra-indications to the use of adrenaline during an allergic emergency.

Warning and precautions: Patients should be advised NOT to inject into the buttocks. Large doses or accidental intravenous injection of adrenaline may result in cerebral haemorrhage due to sharp rise in blood pressure. Accidental injection into the hands or feet may result in loss of blood flow to the affected areas. If there is an accidental injection into these areas, advise the patient to go immediately to the nearest A & E or hospital casualty department for treatment. All patients who are prescribed EpiPen® should be thoroughly instructed to understand the indications for use and the correct method of administration. It is strongly advised to educate the patient’s parents, caregivers, teachers, for the correct usage, in case support is needed in the emergency. In case of injection performed by a caregiver, patient’s leg should be kept still to reduce risk of injection site injury. The needle should never be reinserted after use.
In patients with a thick sub-cutaneous fat layer, there is a risk for adrenaline not reaching the muscle tissue resulting in a suboptimal effect. A second injection with an additional EpiPen® may be needed. Use with extreme caution in patients with heart disease and those taking digitalis, mercurial diuretic or quinidine. Adrenaline should only be prescribed to these patients and the elderly if the potential benefit justifies the potential risk. There is a risk of adverse reactions following adrenaline administration in patients with high intraocular pressure, severe renal impairment, prostatic adenoma leading to residual urine, hypercalcaemia and hypokalaemia. In patients with Parkinson’s disease, adrenaline may be associated with a transient worsening of Parkinson’s symptoms such as rigidity and tremor. Anginal pain may be induced by adrenaline in patients with coronary insufficiency. Hyperthyroid individuals (hyperfunction of the thyroid gland), individuals with cardiovascular disease, hypertension (raised blood pressure), or diabetes, elderly individuals, pregnant women, and children under 25 kg body weight using EpiPen® and children under 7.5 kg body weight using EpiPen® Jr. auto injector may theoretically be at greater risk of developing adverse reactions after adrenaline administration. The patient/carer should be informed about the possibility of biphasic anaphylaxis which is characterised by initial resolution followed by recurrence of symptoms some hours later. Asthmatic patients may be at increased risk of severe anaphylactic reaction. Patients should be warned regarding related allergens and investigated so that their specific allergens can be characterised. Children under 15 kg in body weight should be carefully monitored for signs of adrenaline overdose (see section 4.9 of SmPC).

Interaction with other medicinal products: Caution is indicated in patients receiving drugs that may sensitise the heart to arrhythmias, including digitalis, mercurial diuretics or quinidine. The effects of adrenaline may be enhanced by tricyclic antidepressants and mono amine oxidase inhibitors (MAO-inhibitors) and catechol-O-methyl transferase inhibitors (COMT-inhibitors), thyroid hormones, theophylline, oxytocin, parasympatholytics, certain antihistamines (diphenhydramine, chlorpheniramine), levodopa and alcohol. Pressor effects of adrenaline may be counteracted by rapidly acting vasodilators or alpha-adrenergic blocking drugs. Adrenaline inhibits the secretion of insulin, thus increasing the blood glucose level. It may be necessary for diabetic patients receiving adrenaline to increase their dosage of insulin or oral hypoglycaemic drugs. The β-stimulating effect can be inhibited by simultaneous treatment with β-blocking drugs.

Pregnancy and lactation: Adrenaline should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus. Adrenaline not expected to have any effect on the nursing infant.

Effects on ability to drive and use machines: Ability to drive and use machines may be affected by the anaphylactic reaction, as well as by possible adverse reactions to adrenaline.

Undesirable effects: (Rare): Stress cardiomyopathy. (Frequency not known): May include injection site infections such as rare cases of serious skin and soft tissue infections, including necrotizing fasciitis and myonecrosis caused by Clostridia (gas gangrene); Anxiety, apprehension, nervousness, headaches, dizziness, tremor and undesirable effects on the central nervous system, tachycardia, cardiac arrhythmia, palpitations, fatal ventricular fibrillation, angina, hypertension, pallor, peripheral ischaemia following accidental injection of the pens in hands or feet; respiratory difficulties, nausea, vomiting, hyperhidrosis, asthenia, accidental injections can lead to injury at the injection site such as bruising, bleeding, discoloration, erythema or skeletal injury.

For a complete list of warnings and adverse reactions, you should consult the Summary of Product Characteristics.

Legal Category: POM Marketing Authorisation Number: EpiPen® Auto-Injector 0.3 mg PL 46302/0171, EpiPen® Jr. Auto-Injector 0.15mg PL 46302/0172 MAH: Mylan Products Ltd., Station Close, Potters Bar, EN6 1TL, UK NHS Price: EpiPen® 0.3 mg and EpiPen® Jr. 0.15mg are available as single unit doses at £60.69 each or as a twin pack of 2 Auto-Injectors at £121.38 Date of Revision of Prescribing Information: July 2024 Veeva Reference: UK-EPI-2024-00006

The SmPC for this product, including adverse reactions, precautions, contra-indications, and method of use can be found at: http://www.mhra.gov.uk/Safetyinformation/Medicinesinformation/SPCandPILs/index.htm and from Viatris Medical Information, Building 4, Trident Place, Hatfield Business Park, Mosquito Way, Hatfield, Hertfordshire, AL10 9UL, phone no. 01707 853000, Email: info.uk@viatris.com

Safety & Tolerability

child park allergy

Contraindications

There are no known absolute contraindications to the use of EpiPen® auto injector during an allergic emergency.1,2

Side Effects

The SPC for EpiPen lists no adverse reactions as very common or common.1,2

For a full list of adverse reactions, precautions, contraindications, and method of use please consult the SPC.1,2

https://www.medicines.org.uk/emc/search?q=epipen

References:

  1. EpiPen® (adrenaline) Auto-Injector 0.3mg Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/4289/smpc. Last accessed: November 2022
  2. EpiPen® Jr (adrenaline) Auto-Injector 0.15mg Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/4290/smpc. Last accessed: November 2022

Clinical Information

EpiPen Family

Guidelines

Adrenaline is the first-line treatment for anaphylaxis and is recommended in the major guidelines including BSACI, Resuscitation Council UK, and EAACI. 1,2,3

Please find below summaries of the following key guidelines relevant to the UK:

MHRA guidelines on adrenaline autoinjectors4

Advice for healthcare professionals:4

  • It is recommended that 2 adrenaline auto-injectors are prescribed, which patients should carry at all times.
  • Ensure that people with allergies and their carers have been trained to use the particular auto-injector that they have been prescribed—technique varies between injectors
  • Encourage people with allergies and their carers to obtain and practise using a trainer device (available for free from the manufacturers’ websites)

MHRA Guidelines

Resuscitation Council UK - Emergency treatment of anaphylactic reactions: Guidelines for healthcare providers2

Standard practice for healthcare professionals, particularly in the hospital is to use a vial of adrenaline, syringe and needle.

Adrenaline (give IM unless experienced with IV adrenaline)
IM doses of 1:1000 adrenaline (repeat after 5 min if no better)

  • Adult 500 micrograms IM (0.5 mL)
  • Child more than 12 years: 500 micrograms IM (0.5 mL)
  • Child 6 -12 years: 300 micrograms IM (0.3 mL)
  • Child less than 6 years: 150 micrograms IM (0.15 mL)

RESUS Guidelines

BSACI guidelines on prescribing an adrenaline autoinjector1

Adrenaline is the first-line treatment for anaphylaxis. It should be used in patients with significant airway involvement or hypotension, occurring as part of an anaphylactic (IgE- or non IgE-mediated) reaction. An auto-injector allows early administration of adrenaline, improving outcome.

BSACI Guidelines

References:

  1. Ewan P et al. BSACI guideline: prescribing an adrenaline auto-injector. Clinical & Experimental Allergy, 46, 1258-1280
  2. Resuscitation Council UK Anaphylaxis Guidelines. Available at: https://www.resus.org.uk/sites/default/files/2021-05/Emergency%20Treatment%20of%20Anaphylaxis%20May%202021_0.pdf. Last accessed: November 2022.
  3. Muraro A, et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. 2014; 69(8): 1026-1045
  4. MHRA Guidelines - https://www.gov.uk/drug-safety-update/adrenaline-auto-injectors-updated-advice-after-european-review Last accessed: November 2022.

Supporting your patient

EpiPen Patient

Viatris has a range of material to support you and your patients.

For patients who have been prescribed EpiPen®:

Click here to order relevant material.

About Allergy

Allergy Image

Allergy

Anaphylaxis

Anaphylaxis Image

Anaphylaxis

UK-EPI-2024-00015 July 2024

Welcome to the Viatris Connect portal for UK healthcare professionals (HCPs) where you’ll find promotional and non-promotional information about Viatris’ portfolio, therapy area materials and professional resources.

I am a UK healthcare professional